Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Abstract

in complex with peptides of hSyt2 and its homolog hSyt1. We demonstrate that neuronal surface receptor binding limits the clinical efficacy of unmodified BoNT/B and that modified BoNT/B proteins have promising clinical potential.